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 Introduction 
 First-line treatment of patients with anaplastic glioma 
and glioblastoma, also referred to as high-grade gliomas, 
has been largely standardized and includes radiation ther-
apy (RT) and the alkylating agent temozolomide (TMZ). 
Whether these treatment modalities are used in a com-
bined approach or rather sequentially depends on the 
WHO grade, age, and molecular markers such as the meth-
ylation status of the O 6 -methylguanine DNA methyltrans-
ferase  (MGMT) gene promoter  [1–3] . In contrast, treat-
ment is much less standardized when the tumor recurs  [4] . 
The antiangiogenic agent bevacizumab has been approved 
for recurrent glioblastoma in the US but not in most Euro-
pean countries  [5] . Other treatment options that are fre-
quently used include reresection  [6] , the administration of 
nitrosoureas such as lomustine  [7–10] , rechallenge with 
TMZ  [11] , and numerous experimental drugs  [12] . In gen-
eral, these treatment options show limited activity. The sit-
uation is particularly challenging in patients suffering from 
repeated relapses who present with sustained good perfor-
mance status seeking further therapy. Here we report our 
institutional experience with the combination of carbopla-
tin and etoposide in heavily pretreated patients with ma-
lignant gliomas at a third or fourth tumor progression.
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 Abstract 
 Background: Treatment of recurrent anaplastic glioma and 
glioblastoma remains a particular challenge in neurooncol-
ogy. The lack of controlled trials results in poor evidence for 
all therapeutic options. Upon recurrence, many patients are 
treated with bevacizumab or one of the frequently used ni-
trosoureas such as lomustine. However, patients who still 
present in overall good condition after failure of multiple 
lines of therapy may ask for additional therapy.  Methods: 
Here, we report our experience with the use of carboplatin 
in combination with etoposide as fourth- or fifth-line thera-
py in patients with progressive high-grade glioma.  Results: 
The median Karnofsky performance status at the beginning 
of treatment was 80%. The median progression-free survival 
(PFS) was 2.5 months. PFS at 6 months was 0%. Administra-
tion of carboplatin and etoposide was associated with grade 
3 or 4 hematotoxicity in 8 of 12 patients.  Conclusion: Carbo-
platin in combination with etoposide has an unfavorable 
risk-benefit profile in heavily pretreated glioma patients. 
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 Patients and Methods 
 We retrospectively reviewed tumor board proceedings from 
2010–2013 and identified 12 patients with recurrent high-grade gli-
oma treated with carboplatin (240 mg/m 2 on day 1) and etoposide 
(100 mg/m 2 on days 2 and 3) every 4 weeks following multiple prior 
therapies. All patients had magnetic resonance imaging (MRI) every 
8–12 weeks or in the case of clinical deterioration. MRI was evalu-
ated according to Response Assessment in Neuro-Oncology (RANO) 
criteria  [13] . Progression-free survival (PFS) was determined from 
the date of treatment start with salvage carboplatin and etoposide 
therapy until the date of further progression according to the Kap-
lan-Meier method. Overall survival (OS) was calculated from the 
initiation of carboplatin and etoposide treatment until death. The 
total OS was determined from the date of the initial surgery to death.
 Results 
 Of the 12 patients, 8 had been diagnosed with glioblas-
toma, 3 with anaplastic astrocytoma, and 1 with anaplas-
tic oligodendroglioma. All patients had a third or fourth 
tumor recurrence when treatment with carboplatin/eto-
poside was initiated. The median age at diagnosis was 50 
years (range 37–68), with a preponderance of males (8 
males and 4 women). Following the initial surgery, fur-
ther therapy lines consisted of RT alone (n = 3, anaplastic 
astrocytoma), RT with concomitant and adjuvant che-
motherapy with TMZ (n = 7, glioblastoma), and RT in 
combination with temsirolimus (n = 1, EORTC 26082, 
NCT01019434, glioblastoma). One patient received no 
adjuvant therapy following surgery because of the initial 
diagnosis of a WHO grade II oligodendroglioma. Upon 
progression to an anaplastic glioma after 22 months, re-
resection was performed with subsequent RT. In the oth-
er patients, second-line therapy comprised reresection 
followed by RT, reexposure to TMZ, or bevacizumab in 
combination with ornatuzumab/placebo (Genentech 
GO27819, NCT01632228). Patients not undergoing rere-
section (n = 7) received TMZ or bevacizumab alone or in 
combination with RO5323441  [14] . Depending on pre-
treatment, third- and fourth-line therapy consisted of 
TMZ, lomustine, bevacizumab alone, or bevacizumab in 
combination with TMZ or lomustine. Carboplatin in 
combination with etoposide was administered as fourth-
line therapy in 3 patients and as fifth-line therapy in 9.
 Detailed patient characteristics are summarized in  ta-
ble 1 . At the time of initiation of carboplatin and etoposide, 
most patients presented in good overall condition with a 
median Karnofsky performance status (KPS) of 80% and 
only 4 out of 12 patients requiring steroid administration. 
Treatment with carboplatin and etoposide was only mod-
erately tolerated and CTCAE grade 3 and 4 hematotoxic-
ity occurred in 67% of the patients. Four patients received 
granulocyte colony-stimulating factor treatment and anti-
biotic prophylaxis for prolonged neutropenia.
 The median PFS of patients receiving etoposide-based 
salvage therapy was 2.5 months. We did not record any 
complete or partial responses and the PFS at 6 months 
was 0%. The median OS after initiation of carboplatin/
etoposide was 3.3 months ( fig. 1 ). The median OS from 
the initial diagnosis was 21.7 months.
 Discussion 
 There is no standard of care for patients with recurrent 
high-grade gliomas. Various drugs and regimens have 
been examined but no standard has been established so 
 Table 1.  Patient characteristics
Patients, n (%)
Sex
Male 8 (67)
Female 4 (33)
Toxicity of carboplatin/etoposide
Grade 3/4 leukopenia and
neutropenia 8 (67)
Treatment with G-CSF for
prolonged neutropenia 4 (33)
KPS upon initiation of carboplatin and etoposide
100 0 (0)
90 5 (42)
80 6 (50)
70 1 (8)
Lines of chemotherapy prior to carboplatin/
etoposide treatment (n)
1 1 (8)
3 5 (42)
4 6 (50)
Steroid use upon initiation of carboplatin and etoposide
No 8 (67)
Yes 4 (33)
MGMT status
Methylated 2 (17)
Unmethylated 4 (33)
Undetermined 6 (50)
IDH1 status
Mutated 1 (8)
Wild type 9 (75)
Undetermined 2 (17)
The median age was 50 years (range 37 – 68). G-CSF = Granu-
locyte colony-stimulating factor.
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far  [15] . Patients who experience repeated tumor pro-
gression may present with a reduced KPS which does not 
allow for further tumor-specific therapy but rather re-
quires a change to best supportive care. However, a con-
siderable number of patients still have a good KPS even 
after failure of multiple prior therapy lines. Here, we ex-
plored the combination of carboplatin and etoposide in 
patients with a third or fourth recurrence of a high-grade 
glioma. Although only a limited number of patients were 
examined, our results do not point to clinically relevant 
activity of such treatment. In contrast, we observed a sig-
nificant toxicity associated with an impaired quality of life 
which required hospitalization of some patients.
 Platinum-based antineoplastic agents alone or in com-
bination with other drugs have been used for the treat-
ment of gliomas for at least 2 decades  [16, 17] . A rather 
intense regimen, including ifosfamide, carboplatin, and 
etoposide (ICE), was administered to patients with high-
grade glioma at a second or third tumor recurrence  [18] . 
Similarly to our findings, no complete or partial respons-
es were observed. In contrast, promising activity of this 
regimen was reported in patients with a first tumor recur-
rence with a 6-month PFS of 35% and a median OS of 10.7 
months from the beginning of ICE  [19] . Activity was also 
reported for carboplatin and etoposide in patients with 
recurrent high-grade glioma after the initial surgical re-
section followed by RT and no prior chemotherapy with 
a 6-month PFS of 20% in a phase 1 study including 30 
patients  [20] .
 Our analysis suggests that the activity of carboplatin 
and etoposide in heavily pretreated patients with high-
grade glioma is low, which may be partially explained by 
the fact that all but one patient had received prior antian-
giogenic treatment with bevacizumab which may have 
precluded benefit from the drugs administered after-
wards  [21, 22] . Instead, severe toxicity was observed, 
which may also reflect residual effects of multiple lines of 
previous therapy in all patients. Similarly to previous 
studies, we used carboplatin at a dose of 240 mg/m 2 on 
day 1  [23] . Area under the curve (AUC)-based dosing 
(Calvert formula) may represent a more suitable way to 
define the best dose of carboplatin in terms of activity and 
tolerability. Still, because of its lack of activity and its neg-
ative impact on the quality of life, the combination of car-
boplatin and etoposide cannot be recommended as a rou-
tine salvage treatment. Thus, novel treatment approaches 
for patients with recurrent gliomas are urgently needed 
and should be the focus of future clinical trials.
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 Fig. 1. PFS and OS of 12 patients with a third or fourth progression 
of high-grade glioma treated with carboplatin and etoposide as 
fourth- or fifth-line therapy (OS is presented with 2 censored cases 
because they were still alive at the time of closure of the database). 
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